Secukinumab
CosentyxRCSB PDB 9SFX · 3D model
Drag to rotate. Scroll or pinch to zoom.
A lab-made antibody that neutralizes IL-17A, an inflammation-driving protein linked to psoriasis and related conditions.
How it works
The body sometimes makes too much of a signaling protein called IL-17A, which tells skin and joint tissue to become inflamed. Secukinumab is an antibody engineered to grab onto IL-17A and stop it from delivering that get-inflamed message. With less IL-17A activity, skin cells stop overgrowing so fast and joints or connective tissue calm down.
What it’s used for
Approved to treat moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, a related spinal condition, enthesitis-related arthritis in children, and hidradenitis suppurativa, a painful skin condition causing recurring boil-like lumps.
- Mechanism
- IL-17A antagonist (mAb)
- Drug class
- Monoclonal antibody
- Therapeutic area
- Immunology